FDA Grants VX15 Fast Track Status for Huntington's Disease

A Phase 2 clinical trial has been initiated, in patients with late prodromal (pre-manifest) and early manifest HD
A Phase 2 clinical trial has been initiated, in patients with late prodromal (pre-manifest) and early manifest HD

The Food and Drug Administration (FDA) has granted Fast Track designation for VX15 (Vaccinex) as a potential treatment for Huntington's disease (HD). 

The Company has initiated a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate VX15 in patients with late prodromal (pre-manifest) and early manifest HD in June 2015. A complete interim analysis of the trial is anticipated in the third quarter of 2016 and detailed data to be available in 2018. 

Related Articles

VX15 is a novel, investigational monoclonal antibody designed to block the activity of semaphorin 4D (SEMA4D), a molecule believed to promote chronic inflammatory responses in the brain.

For more information visit Vaccinex.com.

Loading links....